Table 1 Patient demographics and baseline characteristics
Patient characteristics | N (30) | % |
|---|---|---|
Median age, years (range) | 61 | (30–79) |
Sex | ||
 Male | 17 | 57 |
 Female | 13 | 43 |
ECOG Performance status | ||
 0 | 18 | 60 |
 1 | 12 | 40 |
MMR status | ||
 pMMR | 21 | 70 |
 dMMR | 1 | 3 |
 Unknown | 8 | 27 |
KRAS Mutation status | ||
 Mutated | 17 | 57 |
 Wild type | 11 | 37 |
 Unknown | 2 | 7 |
BRAF Mutation status | ||
 V600E | 1 | 3 |
 Wild type | 20 | 67 |
 Unknown | 9 | 30 |
Median lines of prior systemic therapy, lines (range) | 3 | (2–5) |
 2 | 14 | 47 |
 3 | 10 | 33 |
 4 | 3 | 10 |
 5 | 3 | 10 |
Previous systemic therapy | ||
 FOLFOX + Bevacizumab | 21 | 70 |
 FOLFIRI + Bevacizumab | 18 | 60 |
 Regorafenib | 10 | 33 |
 FOLFOX | 6 | 20 |
 FOLFIRI + Ziv-aflibercept | 4 | 13 |
 FOLFIRI + Cetuximab | 3 | 30 |
 Other | 18 | 60 |